Because STAT3 signaling has been implicated in therapeutic resistance to several different cancer treatments, ongoing efforts to target receptor tyrosine kinase signaling networks in NSCLC would likely be improved by combination with ruxolitinib or other JAK family inhibitors [14], [15], [44]. This evidence concerns the gene STAT3 and cancer.